基因变异的评估与与硫氨酸相关的胰腺炎的风险相关:来自ENEIDA注册表的病例对照研究
Iván Guerra1, Francisco Barros2, María Chaparro3,4
1Hospital Universitario de Fuenlabrada, Madrid, Spain.
Digestive diseases (Basel, Switzerland)
|March 7, 2024
概括
遗传因素似乎无法预测在炎症性肠病 (IBD) 患者中提奥普林诱导的胰腺炎. 这项研究发现IBD患者与没有胰腺炎之间的胰腺炎相关基因变异没有显著差异.
科学领域:
- 胃肠病学 胃肠病学
- 药物遗传学 药物遗传学
- 遗传学 遗传学 是一个
背景情况:
- 在炎症性肠病 (IBD) 患者中,氨酸诱导的胰腺炎的危险因素尚不清楚.
- 识别预测性药物遗传标记对于患者安全至关重要.
研究的目的:
- 为了评估IBD患者的胰腺炎的预测性药物遗传风险,治疗与 thiopurines.
- 调查特定基因在与硫氨酸相关的胰腺炎中的作用.
主要方法:
- 对IBD患者急性胰腺炎的观察性药物遗传学研究,这些患者接受了提奥普林治疗.
- 在8个胰腺炎相关基因 (CASR,CEL,CFTR,CDLN2,CTRC,SPINK1,CPA1,PRSS1) 的完整测序.
- 胰腺炎病例与来自ENEIDA注册表的对照病例之间的遗传变异的比较.
主要成果:
- 分析了95个病例和105个对照组.
- 在病例和对照之间没有观察到罕见的致病性或未知意义变异的显著差异.
- 在CASR,CPA1,PRSS1和SPINK1中没有发现导致胰腺炎的变异;没有检测到致病性CFTR突变.
结论:
- 已知与胰腺炎相关的基因似乎不参与IBD患者与氨酸相关的胰腺炎的发生.
- 可能需要进一步的研究来确定其他遗传或非遗传风险因素.
相关概念视频
Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Chronic Pancreatitis I: Introduction
26
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80%...
26
Chronic Pancreatitis II: Pathophysiology
30
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
30


